Related Experiment Video
Updated: Mar 19, 2026
08:56
Evaluating the Role of Mitochondrial Function in Cancer-related Fatigue
Published on: May 17, 2018
9.7K
Treatment-associated Fatigue in Cancer Patients Treated with Immune Checkpoint Inhibitors; a Systematic Review and
O Abdel-Rahman1, D Helbling2, J Schmidt3
1Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt; OncoCentrum Zurich, Gastrointestinal Tumor Center Zurich (GITZ), Zurich, Switzerland.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|June 25, 2016
Summary
Immune checkpoint inhibitors can cause fatigue. CTLA-4 inhibitors increase fatigue risk, while PD-1 inhibitors decrease it, according to this meta-analysis.
Area of Science:
- Oncology
- Immunology
- Clinical Trials
Background:
- Fatigue is a significant side effect of immune checkpoint inhibitors (ICIs).
- Understanding the differential risk of fatigue associated with various ICIs is crucial for patient management.
Purpose of the Study:
- To assess the risk of fatigue in patients treated with immune checkpoint inhibitors.
- To compare the fatigue risk associated with CTLA-4 inhibitors versus PD-1 inhibitors.
Main Methods:
- A meta-analysis of randomized phase II and III trials was conducted.
- Data from Medline and Google Scholar were systematically reviewed.
- Included trials involved cancer patients treated with ipilimumab, nivolumab, pembrolizumab, or tremelimumab.
Main Results:
- CTLA-4 inhibitors were associated with increased odds of all-grade (OR 1.23) and high-grade fatigue (OR 1.72).
- PD-1 inhibitors were associated with decreased odds of all-grade (OR 0.72) and high-grade fatigue (OR 0.36).
Conclusions:
- CTLA-4 inhibitors appear to elevate the risk of fatigue compared to control regimens.
- PD-1 inhibitors seem to reduce the risk of fatigue compared to control regimens.
Related Concept Videos
01:27Tumor Immunotherapy
2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
02:56Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
02:56Treatment Resistent Cancers
1.5K
1.5K
01:30Cancer Vaccines
1.3K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K
02:49Cancer Therapies
10.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.6K
02:49Cancer Therapies
3.0K
3.0K